Haploidentical stem cell transplantation (SCT) offers a transplantation option to patients who lack an HLA-matched donor. We developed a 2-step approach to myeloablative allogeneic hematopoietic stem cell transplantation for patients with haploidentical or matched related (MR) donors. In this approach, the lymphoid and myeloid portions of the graft are administered in 2 separate steps to allow fixed T cell dosing. Cyclophosphamide is used for T cell tolerization. Given a uniform conditioning regimen, graft T cell dose, and graft-versus-host disease (GVHD) prophylaxis strategy, we compared immune reconstitution and clinical outcomes in patients undergoing 2-step haploidentical versus 2-step MR SCT. We retrospectively compared data on patients undergoing a 2-step haploidentical (n ¼ 50) or MR (n ¼ 27) peripheral blood SCT for highrisk hematological malignancies and aplastic anemia. Both groups received myeloablative total body irradiation conditioning. Immune reconstitution data included flow cytometric assessment of T cell subsets at day 28 and 90 after SCT. Both groups showed comparable early immune recovery in all assessed T cell subsets except for the median CD3/CD8 cell count, which was higher in the MR group at day 28 compared with that in the haploidentical group. The 3-year probability of overall survival was 70% in the haploidentical group and 71% in the MR group (P ¼ .81), while the 3-year progression-free survival was 68% in the haploidentical group and 70% in the MR group (P ¼ .97). The 3-year cumulative incidence of nonrelapse mortality was 10% in the haploidentical group and 4% in the MR group (P ¼ .34). The 3-year cumulative incidence of relapse was 21% in the haploidentical group and 27% in the MR group (P ¼ .93). The 100-day cumulative incidence of overall grades II to IV acute GVHD was higher in the haploidentical group compared with that in the MR group (40% versus 8%, P < .001), whereas the grades III and IV acute GVHD was not statistically different between both groups (haploidentical, 6%; MR, 4%; P ¼ .49). The cumulative incidence of cytomegalovirus reactivation was also higher in the haploidentical group compared to the MR group (haploidentical, 68%; MR, 19%; P < .001). There were no deaths from GVHD in either group. Using an identical conditioning regimen, graft T cell dose, and GVHD prophylaxis strategy, comparable early immune recovery and clinical outcomes were observed in the 2-step haploidentical and MR SCT recipients. Ó
INTRODUCTION
Allogeneic stem cell transplantation (SCT) offers a potentially curative therapy for patients with hematological disorders, but it is limited by the lack of available, matched HLA-related donors for many patients. Matched unrelated, haploidentical, and cord blood donors have been used as alternatives with varying levels of success. Haploidentical SCT (haploSCT) has the advantage of rapid availability, relatively lower cost, and widespread access utilizing siblings, parents, or offspring [1] .
Historically, haploSCT was associated with poor outcomes with high rates of high-grade acute graft-versus-host disease (GVHD) [2] [3] [4] . HaploSCT became a viable treatment option when T celledepletion techniques were developed to decrease the incidence of severe GVHD [5] [6] [7] and antithymocyte globulin was added to increase engraftment rates [8, 9] . However, the lymphodepletion associated with these methods resulted in delayed immune recovery and, consequently, a high incidence of post-SCT infectious complications and nonrelapse mortality (NRM) [10] [11] [12] .
In recent years, haploSCT approaches that attenuate rather than deplete T cells from donor grafts have resulted in less infectious mortality and improved patient outcomes [13] [14] [15] [16] [17] . The use of post-SCT cyclophosphamide, which preferentially depletes alloreactive T cells, has been revolutionary in decreasing the incidence of mortality from GVHD and infection after haploSCT [18] . Subsequently, some studies have shown comparable outcomes after haploSCT with cyclophosphamide tolerization when compared with matched related (MR) and matched unrelated SCT [19] [20] [21] . Although the intent of these studies was to highlight the safety of haploSCT using cyclophosphamide as GVHD prophylaxis, they are characterized by the use of heterogeneous stem cell sources and, by extension, T cell doses, conditioning intensities, and GVHD prophylaxis among the comparison groups. As a result, it is difficult to draw firm conclusions about the quality of outcomes between 1 donor source versus another.
Several studies have reported relapse rates in excess of 50% in post-SCT cyclophosphamide trials, possibly due to the use of nonmyeloablative conditioning, the lower dose of T cells associated with a marrow graft, or a combination of both [18, 22] . These findings have stimulated the use of myeloablative conditioning and/or peripheral blood stem cells grafts to decrease relapse rates. Relapse rates are less than 40% in some trials after haploidentical SCT using peripheral blood stem cells as a graft source, which contain higher T cell doses than marrow grafts [23, 24] . These results suggest that there is a range of T cell doses that is important for graft-versus-tumor (GVT) effects in haploSCT [24] [25] [26] . Standardization of T cell doses would allow more effective comparisons of haploSCT regimens and strengthen the ability to compare GVT effects among the various donor sources.
To address these issues, we developed a "2-step" myeloablative peripheral blood approach to SCT in which the lymphoid and myeloid portions of the graft are administered separately [27] . In this approach, a fixed T cell infusion containing 2 Â 10 8 cells/kg CD3 þ cells (SCT step 1) is administered, followed 2 days later by cyclophosphamide to eradicate alloreactive donor and surviving recipient T cells. A CD34-selected product (containing <5 Â 10 4 /kg T cells) is then administered 24 hours after the completion of cyclophosphamide (SCT step 2). This approach has 2 unique features. First, it allows separate control over the infused T cell dose and CD34 stem cell dose. This could allow future studies to titrate the infused T cell dose or CD34 stem cell dose. Second, it spares the stem cell product from exposure to cyclophosphamide, which may help accelerate count recovery. Although high-dose cyclophosphamide is not toxic to stem cells because of high levels of expression of aldehyde dehydrogenase enzyme [28] , it is unknown if this holds true for the more committed progenitor cells that could potentially get damaged by cyclophosphamide and lead to slower engraftment.
In 2008, we initiated a 2-step trial using MR donors with identical T cell dosing, conditioning regimen, and GVHD prophylaxis strategy as our haploidentical study. This trial investigated whether this type of approach could lower GVHD incidence and severity in recipients of MR grafts. Given the identical conditioning regimen, graft T cell dose, and GVHD prophylaxis regimens used in both the haploSCT and MR trials, we retrospectively compared the immune recovery and clinical outcomes in both groups in this current study. We hypothesized that immune recovery would be similar in both groups when an identical transplantation approach is used, including an identical T cell dose, and that this could, in turn, translate into similar survival rates. If NRM rates were equivalent, this would facilitate future prospective trials examining differences in GVT effects between both groups.
METHODS

Design
The Thomas Jefferson University institutional review board approved both the 2-step haploidentical SCT and the 2-step MR research protocols. All patients signed an informed consent as a part of their enrollment on the 2-step clinical trials in accordance with the Declaration of Helsinki. In this retrospective study, all adult patients who underwent a myeloablative peripheral blood haploSCT or MR SCT using the 2-step approach (n ¼ 87) for high-risk hematological malignancies or aplastic anemia were considered for inclusion. Patients were excluded if they had active leukemia at the time of transplantation (9 patients in the haploSCT group and 1 in the MR group) because the small numbers did not allow meaningful comparisons among these high-risk patients. The remaining 77 patients (50 in the haploSCT group and 27 in the MR SCT group) were included in this study. All patients were treated at Thomas Jefferson University Hospital between March 2007 and December 2014.
Transplantation Protocol and the 2-Step Approach
The myeloablative conditioning regimen consisted of 12 Gy of total body irradiation administered in 8 fractions over 4 days. A large fixed T cell dose (2 Â 10 8 cells/kg) was administered after the last fraction of total body irradiation (SCT step 1), followed 2 days later by cyclophosphamide 60 mg/ kg/day for 2 days ( Figure 1) . A CD34-selected donor stem cell product was infused 24 hours after the completion of cyclophosphamide on day 0 (SCT step 2). Before 2010, CD34 selection was accomplished using the Isolex 300i magnetic cell selection system (Baxter, Deerfield, IL). Starting in 2010, the CliniMacs CD 34 Reagent System (Miltenyi Biotec, Bergisch Gladbach, Germany) was used for this purpose under Investigational Device Exemptions (IDEs) 14336 and 15721. Tacrolimus and mycophenolate mofetil were initiated on day À1 for GVHD prophylaxis. All patients received growth factor support (granulocyte macrophage colonyestimulating factor 250 mg/m 2 )
starting on day þ1. In the absence of GVHD, mycophenolate mofetil was discontinued on day 28 and, in the absence of GVHD, a tacrolimus taper was initiated on day þ60 after SCT.
Endpoints
The primary objective was comparative assessment of early immune recovery in recipients of haploSCT versus that after MR SCT. The primary endpoint was immune recovery as measured by quantitative measurement of the CD3/CD4, CD3/CD8, NK bright , and NK dim cell counts on days 28 and 90 after SCT using flow cytometry. The immune recovery panel values were used when done within 1 week from day 28 or 2 weeks from day 90. The secondary endpoint was to compare clinical outcomes between both groups including acute GVHD, chronic GVHD, relapse rate, NRM, relapse-related mortality (RRM), and overall survival (OS). Patients who relapsed or had mixed chimerism on day 28 or 90 were removed from the immune reconstitution analysis but were included in the outcomes analysis.
Definitions
Acute GVHD was assessed using the Glucksberg grading criteria [29] . Chronic GVHD was assessed using the National Institutes of Health consensus criteria for GVHD [30] . White cell engraftment was defined as an absolute neutrophil count of more than 0.5 Â 10 9 /L for at least 3 consecutive days after transplantation. Platelet engraftment was defined as a platelet count more than 20,000/mL without a platelet transfusion for the 7 preceding days.
Statistical Methods
Groups were compared with respect to baseline clinical and demographic characteristics using Pearson's chi-square test or Fisher's exact test. Cell counts of CD3/CD4, CD3/CD8, CD56 bright , and CD56 dim were compared between the HaploSCT and MR groups using the Mann-Whitney test. OS was defined as the time from day 0 after transplantation to death from any cause. OS was estimated using the Kaplan-Meier method, and the log-rank test was used to test for differences in survival between the haploSCT and MR groups. Cumulative incidences of relapse, acute GVHD grades II to IV, and acute GVHD grades III and IV were calculated using death as a competing risk. Competing risk analysis was performed using the freely available EZR software version 1.24 using the Gray test [31] . All other analyses were performed using SPSS version 21.
RESULTS
Patient Population
The patient characteristics and indications for SCT are summarized in Table 1 . The median follow-up was 3 years and 2 months (range, 13 to 95 months) in the haploSCT group and 4 years (range, 1 to 76 months) in the MR group. Donors for the haploSCT patients tended to be younger compared to those for the MR group (median age, 36 years versus 47 years). Both groups received an identical T cell dose (2 Â 10 8 /kg) in step 1 of the SCT. The CD34 cell dose in step 2 of the SCT was similar (median dose, 4.45 versus 4.9 Â 10 6 /kg in the haploSCT and MR groups, respectively, P ¼ .80). The T cell content in the CD34-selected product (step 2) was minimal in both groups (median content, 3.35 Â 10 3 /kg and 3.59 Â 10 3 /kg in the haploSCT and MR groups, respectively).
Immune Recovery in the HaploSCT and MR Setting
The CD3/CD8 cells were higher in the MR group at day 28 compared to the haploSCT group (median 98 versus 39 cells/uL, P ¼ .029). Otherwise, the immune recovery among all other T cell subsets including CD4 
Transplantation Outcomes Engraftment
Successful engraftment was seen in 96% and 100% of haploSCT and MR SCT patients, respectively. The median time to ANC recovery was 11 days in both groups and the median platelet recovery was 17 and 18 days in the haploSCT and MR groups, respectively.
Haploidentical immunological storm
During the 2 days of rest after the donor lymphocyte infusion, a "haploidentical immunological storm," characterized by high fever (median, 103.5 F; range, 99.4 F to 105.5 F), diarrhea, and skin rash, was observed in the haploSCT group and consistently resolved with the administration of cyclophosphamide. With the exception of 1 patient in the haploSCT group, all others developed a fever >100.4 F. The fever only lasted for 2 days, during which time the patients were managed conservatively with particular attention to fluid balance and no steroids were used. This syndrome was not observed in the MR group, although some patients in this cohort experienced low-grade fevers (median, 99.6 F) during this time. þ cells/kg. This is followed by 2 days of rest and then 2 doses of high-dose cyclophosphamide. A CD34-selected stem cell product is then infused.
Acute and chronic GVHD
The 100-day cumulative incidence of overall grades II to IV acute GVHD was higher in the haploSCT compared to the MR group (40% versus 8%, P < .001) (Table 2, Figure 3A) . Thirty-three percent of the acute GVHD in the haploSCT group was due to single-organ grade II skin GVHD. Skin GVHD quickly responded to steroids or steroids plus photopheresis in all patients.
The 100-day cumulative incidence of grades III and IV acute GVHD was similar in both the haploSCT and MR groups (6% versus 4%, P ¼ .49) (Table 2, Figure 3B ). There was a single patient in the haploSCT group with grade 4 acute GVHD with skin and liver involvement that responded completely to steroids. None of the patients in the MR group experienced grade IV acute GVHD. There were no deaths in either group from acute GVHD.
The cumulative incidence of chronic GVHD at 2 years was not statistically different between the haploSCT and the MR groups (19% in the haploSCT group versus 12% in the MR group, P ¼ .47); nor was the 2-year incidence of severe chronic GVHD (4% in the haploSCT group versus 8% in the MR group, P ¼ .49) ( Table 2 ; Figure 3C ,D).
OS and disease control
The 3-year OS was 70% in the haploSCT group versus 71% in the MR group (P ¼ .81) and the 3-year progressionfree survival was 68% versus 70%, respectively (P ¼ .97) ( Figure 4A,B) . The primary cause of death in both groups was relapsed disease with a 3-year cumulative incidence of RRM of 21% in the haploSCT group versus 25% in the MR group (P ¼ .69). The 3-year cumulative incidence of NRM was low in both groups (10% in the haploSCT group versus 4% in the MR group, P ¼ .34) ( Figure 5B ). There were no deaths from GVHD ( Table 2 ). The 3-year cumulative incidence of relapse was comparable in both groups (27% in the MR group versus 21% in the haploSCT group, P ¼ .93) ( Figure 5A ).
CMV reactivation
Cytomegalovirus (CMV) reactivation was determined using PCR measurement of the viral load. Based on seropositivity of the recipient, donor, or both, 34 patients in the haploSCT and 18 patients in the MR groups were at risk for CMV reactivation. CMV reactivation among these patients was higher in the haploSCT group compared with those in the MR group (cumulative incidence 67% versus 19%, P < .001). The median time to develop CMV viremia was 26 days in the haploSCT group and 36 days in the MR group. There were no new primary CMV infections in CMVseronegative patients undergoing SCT from CMV-negative donors in both groups. Among haploSCT recipients, CMV reactivation was similar among patients with evidence of acute GVHD (cumulative incidence, 68%) and without evidence of aGVHD (cumulative incidence, 65%) (P ¼ .78). Pre-emptive anti-CMV therapy was initiated in both groups when CMV PCR was detected on routine surveillance, and no CMV tissue disease was encountered using this strategy.
DISCUSSION
The aim of this study was to compare early immunological recovery and clinical outcomes after haploSCT versus those after MR SCT. Strengthening this analysis was the homogeneity of the treatment in the 2 groups. To our knowledge, this is the first analysis to compare early immune recovery and clinical outcomes between haploSCT versus MR SCT using similar doses of peripheral blood mobilized CD34 cells and identical conditioning regimens, identical GVHD prophylaxis, and utilizing the unique 2-step approach with identical T cell doses. Based on this uniformity, we hypothesized that immune recovery and other clinical outcomes would be similar after haploSCT versus MR SCT. Although we noted some key differences in immune reconstitution and GVHD incidence, our analysis supports this hypothesis.
There were no significant differences in quantitative recovery measures among most immune cell subsets by day 28 and day 90. This early immune recovery was associated with a similarly low infectious mortality in both groups, suggesting a meaningful qualitative immune recovery as well. Higher CD3/CD8 counts at day 28 were observed in the MR group than in the haploSCT group. This difference may be due to a greater proportion of CD3/CD8 cells being activated after the donor lymphocyte infusion and eligible for elimination by cyclophosphamide in the more HLA-disparate haploSCT recipient-donor pairs. Nevertheless, this finding did not result in differences in infectious mortality between the groups. Our results agree with those from a recent study by Di Stasi et al., demonstrating similar immunological recovery among bone marrow haploSCT compared to matched unrelated or MR donor sources [21] . Differences were also noted in the rate of CMV reactivation between the 2 groups. Although no patient in either cohort developed CMV tissue disease or died from CMV infection, CMV reactivation was significantly more prevalent in the haploSCT group. This finding agrees with those from other studies reporting a higher incidence of CMV reactivation in patients receiving a haploSCT [33, 34] .
In our study, the higher frequency of CMV reactivation in the haploidentical compared with that in the MR group was not related to an increased number of CMV-positive donors or recipients or to the occurrence of GVHD. Similarly, it does not appear to be related to the pace of lymphocyte recovery or the absolute number of lymphocyte subsets in these 2 groups. It is possible that during the immuno-storm, which occurs in the haploidentical but not MR patients, more significant depletion of recipient antigen-presenting cells (APCs) renders the haploidentical recipients more vulnerable until APC populations are repopulated. Alternatively, it is possible that HLA disparity reduces the efficiency of T cell interactions with host APCs or tissues early on after transplantation. Although both groups achieve control of CMV with time and with removal of immune suppression, elucidation of the pathogenic mechanisms underlying this higher frequency is warranted because CMV reactivation remains a significant cause of morbidity.
Our secondary objective was to compare clinical outcomes between the 2 groups. Engraftment was prompt in all patients with the use of a myeloablative conditioning regimen and the high donor T cell dose. The less than 100% engraftment rate for the haploSCT group was based on rejection in the presence of donor-specific HLA antibodies in 2 patients treated on the initial study in 2009. Since that time, patients undergoing haploSCT are rigorously screened for donor-specific HLA antibodies, resulting in nearly universal engraftment despite the mismatched graft.
With comparable engraftment and early immunological recovery in both groups, we evaluated next whether this would translate into similar rates of survival in both groups. There was a higher incidence of grades II to IV acute GVHD in the haploSCT group (40%) than in the MR group (8%). This higher incidence of acute GVHD did not affect survival or NRM rates given that there were no deaths from acute GVHD in either group. This seemingly paradoxical finding is accounted for by the fact that the majority of the acute GVHD in the HaploSCT group was grade II single-organ skin involvement, which was easily controlled in all patients with steroids or steroids plus photopheresis. In fact, the incidence of grades III and IV acute and chronic GVHD were not significantly different between both groups (8% versus 4% and 21% versus 14%, respectively). In addition, the overall incidence of grades II to IV acute GVHD in the MR group in this cohort was extremely low compared with what would be expected in an HLA MR or matched unrelated donor (MUD) SCT using conventional GVHD prophylaxis. These rates have historically ranged from 30% to 40% in MR SCT and up to 60% in MUD SCT, according to a recent Center for International Blood and Marrow Transplant Research analysis [35, 36] .
We found no differences in the 3-year OS or progressionfree survival in patients undergoing haploSCT versus MR SCT because of similar 3-year NRM and RRM in both groups. Both groups received myeloablative conditioning, yet the 3-year NRM was very low in both groups (10% and 4% in the HaploSCT and MR group, respectively), possibly because both groups of patients were relatively young (49 years in both groups). We did not observe a difference in the incidence of relapse between the 2 groups in the setting of a uniform conditioning regimen and identical graft T cell dose. The major cause of death in all patients was relapsed disease rather than nonrelapse complications. These findings contrast sharply to earlier experiences with T celledepleted haploSCT, where NRM was a major obstacle to long-term survival because of delayed immune recovery and high infectious mortality [10] [11] [12] .
Our findings are in agreement to those from 2 recent articles by Bashey et al. and Di Stasi et al. who noted similar OS rates when comparing bone marrow haploSCT using post-transplantation cyclophosphamide to either MR or MUD SCT using conventional GVHD prophylaxis [19, 21] . Unlike the findings in our analysis, they reported a similar overall grades II to IV acute GVHD rate and an even lower chronic GVHD rate in the haploSCT compared with either MR or MUD SCT [18] . As previously noted, these differences may be because the MR and MUD groups in these studies received conventional GVHD prophylaxis and not posttransplantation cyclophosphamide.
The limitations of our analysis include its retrospective nature, in which there were potentially undetected influences on study outcomes and confounders of differences between groups, and the small number of subjects, especially in the MR SCT group, which decreased the power to detect differences between both groups. The analysis took place at a single institution, which increased consistency in the treatment of the comparison groups but limited the number of subjects available for analysis.
In conclusion, we found comparable early immune recovery and clinical outcomes in patients receiving peripheral blood haploSCT and after MR SCT using an identical SCT approach. The findings at our institution and others suggest that the use of a haploidentical donor is a safe alternative donor option. Although RRM and NRM were not significantly different between the 2 groups, SCT-related morbidity was observed in the haploSCT group in the form of a greater rate of CMV reactivation and a higher incidence of grade II acute GVHD. The comparable outcomes suggest that haploSCT should be considered for the same clinical indications and disease states as MR SCT. Finally, a prospective randomized multicenter trial comparing haploSCT and MUD SCT including both clinical and cost of care endpoints now appears warranted to assess where and when these options should be utilized for patients requiring SCT but lacking a matched sibling donor.
